[{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"Apnimed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Sulthiame","moa":"CA2","graph1":"Sleep","graph2":"Phase II","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Desitin Arzneimittel \/ Apnimed","highestDevelopmentStatusID":"8","companyTruncated":"Desitin Arzneimittel \/ Apnimed"}]

Find Clinical Drug Pipeline Developments & Deals for Sulthiame

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Through the acqusition, Apnimed will focus on clinical development of Ospolot (sulthiame), which is being evaluated in mid-stage for the treament of obstructive sleep apnea.

                          Product Name : Ospolot

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 25, 2025

                          Lead Product(s) : Sulthiame

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase II

                          Sponsor : Apnimed

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank